It will see the target price IF its approved and sales commence. Thats when the market will start to price in its potential. Can't expect it to happen now in this market environment, especially when its a non-exciting development with limited 'revenue' potential. (ie, its not an alzheimer or cancer drug for example)..
So between now and say the next 3 months, sell covered calls, get what you can for them to reduce your cost basis while you wait.
In the meantime, check out CRMD. Its a gift at $3, target price on it ranges from $20-25 on initial approval. IF they didn't run into quality issues at the manufacturers they chose to use to produce the compound, they would be $20 already, but it delayed their approval. And on top of it, this target price is based on less than 1/2 of its potential market. I know the company is already working on how to get approved for its potential total market, and the target price for that is north of $35-40/sh..
as a disclaimer: I am loaded up on CRMD shares, and just added some down here at $3 the other day. But they are looking at up to another 6-8 months for another go at the fed DEATH agency for consideration (death agency after how they 'approved' the use of the pfizer jab solution that has been hurting and killing folks, and yet the fdeath agency won't pull it from being used)
News 
Market Data 
Discover 
AI
